Antimetabolites: A new perspective

Peter D. Cole; John A. Zebala; Barton A. Kamen

doi:10.1016/j.ddstr.2005.11.004

Antimetabolites: A new perspective

Peter D. Cole, John A. Zebala, Barton A. Kamen

Cancer Institute of New Jersey (CINJ), Pediatric Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Antimetabolites remain as mainstays in our chemotherapeutic armamentarium. Recent approval of several nucleoside analogs and antifolates serve to highlight the progress made in the past 60 years but more importantly their pharmacology/biochemistry reminds us of the complexity of the pathways involved. Antimetabolites should be considered as specific targeting agents in the emerging arena of metabolomics and as tools to more completely understand cellular metabolism.

Original language	English (US)
Pages (from-to)	337-342
Number of pages	6
Journal	Drug Discovery Today: Therapeutic Strategies
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/j.ddstr.2005.11.004
State	Published - 2005

All Science Journal Classification (ASJC) codes

Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.1016/j.ddstr.2005.11.004

Cite this

@article{bac9b8748417455b8bdb0db3501a380f,

title = "Antimetabolites: A new perspective",

abstract = "Antimetabolites remain as mainstays in our chemotherapeutic armamentarium. Recent approval of several nucleoside analogs and antifolates serve to highlight the progress made in the past 60 years but more importantly their pharmacology/biochemistry reminds us of the complexity of the pathways involved. Antimetabolites should be considered as specific targeting agents in the emerging arena of metabolomics and as tools to more completely understand cellular metabolism.",

author = "Cole, {Peter D.} and Zebala, {John A.} and Kamen, {Barton A.}",

note = "Funding Information: P.D.C. is a Damon Runyon-Lilly Clinical Investigator, supported in part by the Damon Runyon Cancer Research Foundation (CI-16-03). B.A.K. is an American Cancer Society Professor. This work was supported in part by an FDA Orphan Products Development grant (FD-R-001832-03) to B.A.K. and by the Institute for Children with Cancer and Blood Disorders, New Brunswick, NJ, USA. ",

year = "2005",

doi = "10.1016/j.ddstr.2005.11.004",

language = "English (US)",

volume = "2",

pages = "337--342",

journal = "Drug Discovery Today: Therapeutic Strategies",

issn = "1740-6773",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Antimetabolites

T2 - A new perspective

AU - Cole, Peter D.

AU - Zebala, John A.

AU - Kamen, Barton A.

N1 - Funding Information: P.D.C. is a Damon Runyon-Lilly Clinical Investigator, supported in part by the Damon Runyon Cancer Research Foundation (CI-16-03). B.A.K. is an American Cancer Society Professor. This work was supported in part by an FDA Orphan Products Development grant (FD-R-001832-03) to B.A.K. and by the Institute for Children with Cancer and Blood Disorders, New Brunswick, NJ, USA.

PY - 2005

Y1 - 2005

N2 - Antimetabolites remain as mainstays in our chemotherapeutic armamentarium. Recent approval of several nucleoside analogs and antifolates serve to highlight the progress made in the past 60 years but more importantly their pharmacology/biochemistry reminds us of the complexity of the pathways involved. Antimetabolites should be considered as specific targeting agents in the emerging arena of metabolomics and as tools to more completely understand cellular metabolism.

AB - Antimetabolites remain as mainstays in our chemotherapeutic armamentarium. Recent approval of several nucleoside analogs and antifolates serve to highlight the progress made in the past 60 years but more importantly their pharmacology/biochemistry reminds us of the complexity of the pathways involved. Antimetabolites should be considered as specific targeting agents in the emerging arena of metabolomics and as tools to more completely understand cellular metabolism.

UR - http://www.scopus.com/inward/record.url?scp=31044455727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31044455727&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2005.11.004

DO - 10.1016/j.ddstr.2005.11.004

M3 - Review article

AN - SCOPUS:31044455727

SN - 1740-6773

VL - 2

SP - 337

EP - 342

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

IS - 4

ER -

Antimetabolites: A new perspective

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this